News

Celltrion announced that the company has successfully selected the most potent antibody candidates to neutralize SARS-CoV-2, the virus causing COVID-19. Through a partnership with…
Read More...

Blackstone and Alnylam Pharmaceuticals, Inc. announced the companies have entered into a broad strategic collaboration under which Blackstone will provide up to $2 billion to support…
Read More...

The U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a genetic…
Read More...

BioNTech SE and Pfizer Inc. today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.…
Read More...

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced it has entered into a clinical collaboration agreement with Bristol Myers Squibb to evaluate…
Read More...

Recipharm announced that Erdosteine will be tested in a clinical study as an add-on treatment for COVID-19 patients. The clinical study, which began on 7th April, is being conducted…
Read More...

Regeneron Pharmaceuticals, Inc. and Zai Lab Limited announced a strategic collaboration for the development and commercialization of REGN1979 (CD20xCD3 bispecific antibody) in mainland…
Read More...

Avacta Group plc announced that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an…
Read More...

Acceleron Pharma Inc. announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sotatercept for the treatment of patients with…
Read More...

Global biotherapeutics leader, CSL Behring and innovative human antibody development company SAB Biotherapeutics (SAB) announced their partnership to combat the coronavirus pandemic…
Read More...

OncoImmune, Inc. has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized…
Read More...

Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, announced a strategic collaboration and…
Read More...

Oxford Biomedica plc announced today it has joined a Consortium led by the Jenner Institute, Oxford University, to rapidly develop, scale-up and manufacture a potential vaccine…
Read More...

Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it has completed an…
Read More...

Cytovia Therapeutics (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer and infectious diseases, announced that it is expanding…
Read More...

HitGen Inc. (HitGen) announced that HitGen and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered into a license agreement to develop a novel class of drugs. This is the second…
Read More...

Gilead Sciences, Inc. announced the completion of the previously announced transaction for Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead (“Purchaser”), to acquire Forty…
Read More...

Gilead Sciences, Inc. and Second Genome announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up…
Read More...

CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of…
Read More...